BioNxt Solutions Prepares for Human Bioequivalence Study For MS
23.4.2025 03:05:00 CEST | ACCESS Newswire | Press release
VANCOUVER, BC / ACCESS Newswire / April 23, 2025 / BioNxt Solutions Inc. ("BioNxt" or the "Company") (CSE:BNXT)(OTC PINK:BNXTF)(FSE:BXT), a bioscience innovator specializing in advanced drug delivery systems, is pleased to report advanced preparation for its human bioequivalence study for its lead Multiple Sclerosis (MS) treatment.
BioNxt's lead product, BNT23001, is a proprietary sublingual thin-film formulation of Cladribine for the treatment of MS. Preclinical studies, as reported in internal research data and third-party evaluations, have demonstrated high absorption rates and bioequivalence compared to existing oral tablet therapies. The Company has purchased Cladribine active pharmaceutical ingredient which is necessary to complete the technology transfer process with Gen-Plus, its European Contract Research and Development Organization (CRDO), in Munich, Germany. Once commenced, the bioequivalence study is relatively short, scheduled for less than 30 days from start to finish.
The Company plans to make further updates in the coming weeks regarding its bioequivalent study preparation and scheduling, as well integration of its research and development operations with Gen-Plus.
BNT23001 offers a novel approach to MS management by addressing limitations in traditional oral therapies. Its sublingual thin-film format provides:
Convenience: Easy-to-use and portable, ideal for patients with difficulty swallowing or active lifestyles.
Rapid Absorption: Direct delivery through the sublingual mucosa for faster therapeutic action.
Improved Compliance: A patient-friendly alternative designed to enhance adherence to prescribed regimens.
By delivering these advantages, BNT23001 aligns with BioNxt's mission to improve outcomes for patients living with chronic diseases like MS.
About BioNxt Solutions Inc.
BioNxt Solutions Inc. is a bioscience innovator focused on next-generation drug delivery technologies, diagnostic screening systems, and active pharmaceutical ingredient development. The Company's proprietary platforms-Sublingual (Thin-Film), Transdermal (Skin Patch), and Oral (Enteric-Coated Tablets)-target key therapeutic areas, including autoimmune diseases, neurological disorders, and longevity.
With research and development operations in North America and Europe, BioNxt is advancing regulatory approvals and commercialization efforts, primarily focused on European markets. BioNxt is committed to improving healthcare by delivering precise, patient-centric solutions that enhance treatment outcomes worldwide.
BioNxt is listed on the Canadian Securities Exchange: BNXT, OTC Markets: BNXTF and trades in Germany under WKN: A3D1K3. To learn more about BioNxt, please visit www.bionxt.com.
Investor Relations & Media Contact
Hugh Rogers, Co-Founder, CEO and Director
Email: investor.relations@bionxt.com
Phone: +1 778.598.2698
Web: www.bionxt.com
LinkedIn: https://www.linkedin.com/company/bionxt-solutions
Instagram: https://www.instagram.com/bionxt
Cautionary Statement Regarding "Forward-Looking" Information
This press release contains forward-looking statements within the meaning of applicable securities laws, including statements regarding the development, testing, regulatory approval, and commercialization of BioNxt's sublingual drug products, as well as projected milestones, anticipated partnerships, and potential market opportunities. Forward-looking statements are inherently subject to significant risks, uncertainties, and assumptions, many of which are beyond BioNxt's control. Factors that could cause actual results to differ materially include, but are not limited to, delays in regulatory approvals, negative outcomes from clinical trials, changes in market demand, fluctuations in funding availability, or disruptions in supply chains. Readers are cautioned not to place undue reliance on these forward-looking statements, as actual results may differ materially from those expressed or implied. BioNxt undertakes no obligation to update or revise forward-looking statements, except as required by law. Factors that could cause actual results to differ materially from those projected include changes in market demand, regulatory developments, delays in clinical trials, fluctuations in financing availability, supply chain disruptions, and unforeseen competitive pressures.
SOURCE: BioNxt Solutions Inc.
View the original press release on ACCESS Newswire
BioNxt Solutions Inc.
Subscribe to releases from ACCESS Newswire
Subscribe to all the latest releases from ACCESS Newswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from ACCESS Newswire
The Inaugural Michelin Guide New Zealand Reveals 1 Two Michelin Stars, 14 One Michelin Star And 35 Bib Gourmands1.7.2026 23:40:00 CEST | Press release
AUCKLAND, NZ / ACCESS Newswire / July 1, 2026 / The inaugural MICHELIN Guide New Zealand 2026 has recognised 110 restaurants across Auckland, Wellington, Christchurch and Queenstown, celebrating exceptional quality, creativity and a strong sense of place. After months of anonymous inspections, the MICHELIN Guide has awarded one restaurant in Queenstown, Essence, Two MICHELIN Stars. Fourteen restaurants have received One MICHELIN Star, 35 have been recognised with a Bib Gourmand for offering good food at great value, and a further 60 are included in the official MICHELIN Guide selection. Gwendal Poullennec, International Director of the MICHELIN Guide, said: "It is rare to award such a quantity of Stars in a country's inaugural launch, New Zealand's performance has been genuinely impressive. The destination presents more than a selection of outstanding restaurants; to our Inspectors, it revealed a contemporary culinary map shaped by unique terroir and a food culture in quiet harmony wit
Clockwork.io Launches The Industry's First Contractual Commitment to End GPU Waste in AI Training1.7.2026 17:00:00 CEST | Press release
"You Only Compute Once" (YOCO) guarantees to resolve 90% of AI training failures with no lost progress, or customers get credit PALO ALTO, CA / ACCESS Newswire / July 1, 2026 / Clockwork.io, pioneer of Software-Driven AI Fabrics™ and the company behind TorchPass AI fault tolerance, today announced the YOCO Guarantee - the industry's first contractual commitment to dramatically reduce the hidden, compounding cost of training failure in large-scale AI infrastructure. The announcement marks a turning point in how the AI industry measures infrastructure reliability - moving beyond uptime metrics designed for a previous era towards goals AI teams value most: whether the job finishes on time, without losing work. Under the YOCO (You Only Compute Once) Guarantee, Clockwork.io commits that at least 90% of training failures on supported TorchPass workloads will be resolved through live GPU migration, with no lost training progress, no checkpoint rollback, and no recompute. If Clockwork.io falls
Hydrosat Launches Data Discovery Platform, Unlocking 500 Million sq km of Satellite Imagery1.7.2026 15:00:00 CEST | Press release
New portal provides on-demand thermal imagery for critical resource monitoring, risk detection, and operational decision-making worldwide. WASHINGTON, D.C. AND LUXEMBOURG CITY, LUXEMBOURG / ACCESS Newswire / July 1, 2026 / Hydrosat, the leading provider of thermal infrared satellite data and AI-powered analytics, today announced the launch of its new Discovery Portal, a centralized gateway for customers to access, explore, and leverage thermal imagery and analytics from space. The Discovery Portal enables organizations to access and evaluate thermal intelligence products powered by Hydrosat's flagship 30 m pixel-size Land Surface Temperature data set and growing constellation of thermal infrared satellites. Unlike traditional optical imagery, thermal imagery captures heat signatures from the Earth's surface, providing actionable insights across vast geographic areas, day or night, and often in conditions where conventional imaging is limited. With over 500 million sq km of imagery alre
Clean Air Metals Files Interim Financial Statements for the Three Months Ended April 30, 202630.6.2026 20:55:00 CEST | Press release
THUNDER BAY, ON / ACCESS Newswire / June 30, 2026 / Clean Air Metals Inc. ("Clean Air Metals" or the "Company") (TSX.V:AIR)(FRA:CKU)(OTCQB:CLRMF) announces that it has filed its unaudited consolidated interim financial statements and management's discussion and analysis for the three-month period ended April 30, 2026, available for viewing on www.sedarplus.ca. Financial Highlights Total assets as at April 30, 2026 of $35,855,341 Total cash as at April 30, 2026 of $664,328 Working capital deficiency as at April 30, 2026 of $2,683,766 Shareholder's equity as at April 30, 2026 of $32,258,687 During the three-month period ended April 30, 2026, the Company incurred $57,783 in cost for exploration activities at the TBN project. During the quarter, the Company has been pursuing project financing alternatives while continuing to advance critical aspects of the project including progressing Advanced Exploration permitting discussions, and detailed planning for the next phase of exploration at E
Sauce Labs Becomes the First Dedicated Software Quality Platform to Achieve ISO 42001 Certification for Responsible AI30.6.2026 17:00:00 CEST | Press release
As AI takes on decisions that used to belong to engineers, the world's largest continuous testing cloud joins the small group of companies in any industry independently certified to govern AI responsibly SAN FRANCISCO, CA / ACCESS Newswire / June 30, 2026 / Sauce Labs, the world's largest continuous testing cloud, today announced it has achieved ISO/IEC 42001 certification, the first international standard for the responsible management of artificial intelligence. The certification covers Sauce AI, including Sauce AI for Insights and Sauce AI for Test Authoring, and makes Sauce Labs the first company dedicated to software quality to bring its AI capabilities under a fully certified AI Management System. Only a small number of companies worldwide, in any industry, have cleared this bar. Software is being written faster than at any point in history, and AI is now making quality decisions that used to belong to engineers. That shift has changed the question enterprise buyers ask. It is no
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom